Brain cancer trial adds spinal-fluid chemo to standard therapy
NCT ID NCT07193654
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a chemotherapy drug (thiotepa) directly into the spinal fluid can help people with glioblastoma that has invaded the brain's ventricles or lining. Participants will first have surgery to remove as much tumor as possible, then receive radiation, oral temozolomide, and the spinal-fluid injections. The goal is to see if this combination improves how long people live without the cancer growing. The trial is currently recruiting 38 adults aged 18–75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
thiotepa (given into the spinal fluid) and temozolomide (oral chemotherapy)
What this could lead to
If it works, this could offer a new treatment option for people with glioblastoma that has spread to the brain's lining or fluid spaces, potentially improving survival.
What could go wrong
This is a small, early-phase study with only 38 participants and no comparison group. The added thiotepa may cause serious side effects like infection or nerve damage, and it is not yet proven to help.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact